JP Morgan Initiates Coverage On C4 Therapeutics with Overweight Rating, Announces Price Target of $10
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsInitiationPrice Target
JP Morgan analyst Anupam Rama initiates coverage on C4 Therapeutics (NASDAQ:CCCC) with a Overweight rating and announces Price Target of $10.
JP Morgan analyst Anupam Rama initiates coverage on C4 Therapeutics (NASDAQ:CCCC) with a Overweight rating and announces Price Target of $10.